Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Aequus Pharmaceuticals Inc V.AQS

Alternate Symbol(s):  AQSZF

Healthcare Drug Manufacturers - Specialty & Generic
Aequus Pharmaceuticals Inc is a Canada based specialty pharmaceutical company. The firm's operating segments are the Commercial platform and Development pipeline. It generates a majority of its revenue from the Commercial platform segment. Aequus is developing a pipeline of products in neurology and psychiatry. The company's launched and pipeline products are Tacrolimus IR, Vistitan, AQS1304, AQS1303, and others.

The Power Play by The Market Herald
{{currentVideo.videoCaption}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (TSXV:AQS)

Fundamentals Snapshot (TSXV:AQS)

Current News (TSXV:AQS)

Aequus Provides General Update and Fiscal 2022 Financial Results

GlobeNewswire May 1, 2023

Aequus Grants Stock Options

GlobeNewswire April 19, 2023

Aequus Announces Financing to Support Launch of Zimed Preservative Free (Bimatoprost 0.03%) and Board Update

GlobeNewswire April 5, 2023

Aequus Pharmaceuticals (TSXV:AQS) receives Health Canada approval

Trevor Abes  December 20, 2022

Aequus Announces Health Canada Notice of Compliance (NOC) for Zimed® Preservative Free (Bimatoprost 0.03%)

GlobeNewswire December 20, 2022

Aequus Reports Third Quarter 2022 Financial Highlights

GlobeNewswire November 29, 2022

Aequus Announces Sandoz Contract Expiry at Year End and Expected Health Canada Approval for Zimed® PF (Preservative Free)

GlobeNewswire November 29, 2022

Aequus Reports Second Quarter 2022 Financial Highlights and General Update

GlobeNewswire August 29, 2022

Press Release for Early Warning Report Regarding Aequus Pharmaceuticals Inc.

GlobeNewswire July 23, 2022
View More News ››

Opinion & Analysis (TSXV:AQS)

No current opinion is available.
View More Opinion ››

Bullboard Posts (TSXV:AQS)

RE:RE:Volume

JohnTool321 - October 16, 2022

RE:RE:New Seeking Alpha report

Lisagerrard17 - May 30, 2022

RE:Volume

Larrymartin77 - May 28, 2022

RE:RE:New Seeking Alpha report

Only that report is just about a year old now.
WsrThanWenYungr - February 17, 2022

RE:New Seeking Alpha report

I saw the report also
BlacknBulls - February 5, 2022

New Seeking Alpha report

New report available on Seeking Alpha: https://seekingalpha.com/article/4417929-aequus-pharmaceuticals-new-products-to-accelerate-growth...
stockwatch99 - April 7, 2021
View more Bullboard ››

Midnight Sun Mining Corp

Midnight Sun Mining Corp

Midnight Sun Mining Corp is an exploration stage company. The company is engaged in the acquisition and exploration of ...
View More »